UNLIMITED TURBO LONG - ASTRAZENECA | Market Closed - Deutsche Boerse AG 11:21:11 2024-05-31 EDT | ||
| 3.3 EUR | +5.43% |
|
| 1 month | +4.10% | ||
| 3 months | +226.73% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 3.3 | +5.43% |
| 24-05-30 | 3.13 | +5.03% |
| 24-05-29 | 2.98 | -3.56% |
| 24-05-28 | 3.09 | -10.95% |
| 24-05-24 | 3.47 | -3.34% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 11:21 am
More quotesStatic data
| Product type | Warrant Knock-Out senza Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
BNP Paribas
|
| WKN | PD669C |
| ISIN | DE000PD669C7 |
| Date issued | 2022-06-13 |
| Strike | 9,442 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.74 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.1 € |
|---|---|
| Lowest since issue | 0.3 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
155.1
USD
Average target price
172
USD
Spread / Average Target
+10.90%
- Stock Market
- Certificates
- Certificat
